Rafa Laboratories To Acquire A Significant Stake In Exceed Orphan And Expand Its International Capabilities In Medicines Addressing Rare Diseases
Acquiring Company
Rafa
Acquired Company
ExCEEd
IsraelBiotechnologyHealth CarePharmaceuticalBiotechnologyHealth CareTherapeuticsDescription
Rafa Laboratories LTD. ("Rafa") and ExCEEd Orphan s.r.o ("ExCEEd") announced today a strategic collaboration for medicines addressing rare diseases in Central and Eastern Europe ("CEE") and Israel. Under the agreement, and as part of its strategy to become an international player, Rafa will invest in ExCEEd an undisclosed amount that shall enable it to strengthen its market access capabilities in the region and move closer to fulfilling its vision to become a leading player in this important mission of pioneering access to patients with rare diseases. Furthermore, the parties shall collaborate on bringing new medicines for rare diseases to both the CEE and Israel.
Quick answer
Rafa is acquiring ExCEEd, announced August 1, 2022. Rafa is based in Israel.
- How much did Rafa pay for ExCEEd?
- The deal value was not disclosed.
- What does Rafa do?
- Founded in 1937 and headquartered in Jerusalem, Israel, Rafa is among the leading pharmaceutical companies in Israel and a global player in emergency solutions – medical countermeasures, supplying auto-injectors for..
- Where are Rafa and ExCEEd based?
- Rafa is based in Israel.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Bristol Myers Squibb And Turning Point Therapeutics Announce Expiration Of Hsr Act Waiting Period And Clearance From Federal Cartel Office Of Germany Related To Pending Acquisition Of Turning Point Therapeutics (August 16, 2022)
- Bristol Myers Squibb Completes Acquisition Of Turning Point Therapeutics, Expanding Precision Oncology Portfolio (August 17, 2022)
- Pfizer To Acquire Global Blood Therapeutics For $5.4 Billion To Enhance Presence In Rare Hematology, $5.4B (August 8, 2022)
- Gurnet Point Capital And Patient Square Capital Complete Their Acquisition Of Radius Health, Inc. (August 15, 2022)
- Amgen To Acquire Chemocentryx For $4 Billion In Cash, $4B (August 4, 2022)
- Gilead Sciences To Acquire Mirobio (August 4, 2022)
Who to call at Rafa, and when
When Rafa changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Rafa raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Rafa, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Rafa. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Rafa makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired ExCEEd?
ExCEEd was acquired by Rafa, based in Israel. The deal was reported on August 1, 2022. Rafa is privately held and operates in Biotechnology.
When did Rafa acquire ExCEEd?
Rafa's acquisition of ExCEEd was reported on August 1, 2022. Rafa Laboratories LTD. ("Rafa") and ExCEEd Orphan s.r.o ("ExCEEd") announced today a strategic collaboration for medicines addressing rare diseases in Central and Eastern Europe ("CEE") and Israel. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does ExCEEd do?
Founded in 2018 and headquartered in Prague, Czech, ExCEEd is focused on innovative treatments for rare diseases and has extensive experience in launching innovative medicines in this field. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.